Post-ERCP pancreatitis: Review of current preventive strategies

Current Opinion in Gastroenterology

Volumn 28, Issue 3, 2012, Pages 280-286

  Feurer, Matthew E ^a   Adler, Douglas G ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

complications; ERCP; pancreatitis; post ERCP pancreatitis

Indexed keywords

ACETYLCYSTEINE; ADRENALIN; ALLOPURINOL; CEFTAZIDIME; DICLOFENAC; GABEXATE; GLUCOCORTICOID; GLYCERYL TRINITRATE; INDOMETACIN; INTERLEUKIN 10; LIDOCAINE; NAFAMSTAT MESILATE; NIFEDIPINE; NONIONIC CONTRAST MEDIUM; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PLACEBO; PROTEINASE INHIBITOR; SECRETIN; SOMATOSTATIN; UDENAFIL; ULINASTATIN; VALDECOXIB;

BALLOON DILATATION; BILIARY TRACT SURGERY; CANNULATION; DRUG EFFICACY; DRUG MEGADOSE; ENDOSCOPIC PAPILLARY BALLOON DILATION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FLUOROSCOPY; GUIDE WIRE; HIGH RISK PATIENT; HUMAN; ODDI SPHINCTER; PANCREAS DUCT; PANCREATITIS; PATIENT SELECTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; STENT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATHETERIZATION; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; FEMALE; HUMANS; MALE; PANCREATIC DUCTS; PANCREATITIS; PATIENT SELECTION; RISK FACTORS; STENTS;

EID: 84859890201     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283528e68     Document Type: Review

References (63)

1. Silviera ML, Seamon MJ, Porshinsky B, et al. Complications related to endoscopic retrograde cholangiopancreatography: a comprehensive clinical review. J Gastrointest Liver Dis 2009; 18:73-82.
2. Arata S, Takada T, Hirata K, et al. Post-ERCP pancreatitis. J Hepatobiliary Pancreat Sci 2010; 17:70-78.
3. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54:425-434. (Pubitemid 33661145)
4. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909-918. (Pubitemid 26314443)
5. Vandervoort J, Soetikno RM, Tham TC, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002; 56:652-656. (Pubitemid 36531698)
6. Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96:417-423.
7. Testoni PA, Mariani A, Giussani A, et al., SEIFRED Group. Risk factors for post-ERCP pancreatitis in high- and low-volume centers and among expert and nonexpert operators: a prospective multicenter study. Am J Gastroenterol 2010; 105:1753-1761.
8. Debenedet AT, Raghunathan TE, Wing JJ, et al. Alcohol use and cigarette smoking as risk factors for postendoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2009; 7:353e4-358e4.
9. Moffatt DC, Coté GA, Avula H, et al. Risk factors for ERCP-related complications in patients with pancreas divisum: a retrospective study. Gastrointest Endosc 2011; 73:963-970.
10. Lukens FJ, Howell DA, Upender S, et al. ERCP in the very elderly: outcomes among patients older than eighty. Dig Dis Sci 2010; 55:847-851.
11. Banerjee N, Hilden K, Baron TH, Adler DG. Endoscopic biliary sphincterotomy is not required for transpapillary SEMS placement for biliary obstruction. Dig Dis Sci 2011; 56:591-595.
12. Cotton PB. Analysis of 59 ERCP lawsuits; mainly about indications. Gastrointest Endosc 2006; 63:378-382. (Pubitemid 43261459)
13. Cennamo V, Fuccio L, Zagari RM, et al. Can early precut implementation reduce endoscopic retrograde cholangiopancreatography-related complication risk? Meta-analysis of randomized controlled trials. Endoscopy 2010; 42:381-388.
14. Gong B, Hao L, Bie L, et al. Does precut technique improve selective bile duct cannulation or increase post-ERCP pancreatitis rate? A meta-analysis of randomized controlled trials. Surg Endosc 2010; 24:2670-2680.
15. Testoni PA, Giussani A, Vailati C, et al. Precut sphincterotomy, repeated cannulation and post-ERCP pancreatitis in patients with bile duct stone disease. Dig Liver Dis 2011; 43:792-796.
16. Disario JA, Freeman ML, Bjorkman DJ, et al. Endoscopic balloon dilation compared with sphincterotomy for extraction of bile duct stones. Gastroenterology 2004; 127:1291-1299. (Pubitemid 39457755)
17. Watanabe H, Yoneda M, Tominaga K, et al. Comparison between endoscopic papillary balloon dilatation and endoscopic sphincterotomy for the treatment of common bile duct stones. J Gastroenterol 2007; 42:56-62. (Pubitemid 46351425)
18. Meister T, Heinzow H, Heinecke A, et al. Post-ERCP pancreatitis in 2364 ERCP procedures: is intraductal ultrasonography another risk factor? Endoscopy 2011 43 331-336.
19. Choudhary A, Bechtold ML, Arif M, et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc 2011; 73:275-282.
20. Mazaki T, Masuda H, Takayama T. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: a systematic review and meta-analysis. Endoscopy 2010; 42:842-853.
21. Zolotarevsky E, Fehmi SM, Anderson MA, et al. Prophylactic 5-Fr pancreatic duct stents are superior to 3-Fr stents: a randomized controlled trial. Endoscopy 2011; 43:325-330.
22. Coté GA, Kumar N, Ansstas M, et al. Risk of post-ERCP pancreatitis with placement of self-expandable metallic stents. Gastrointest Endosc 2010; 72:748-754.
23. Moffatt DC, Coté GA, Fogel EL, et al. Acute pancreatitis after removal of retained prophylactic pancreatic stents. Gastrointest Endosc 2011; 73:980-986.
24. Moffatt DC, Pradermchai K, Avula H, et al. Moderate and severe postendoscopic retrograde cholangiopancreatography pancreatitis despite prophylactic pancreatic stent placement: the effect of early prophylactic pancreatic stent dislodgement. Can J Gastroenterol 2011; 25:215-219.
25. Adler DG, Verma D, Hilden K, et al. Dye-free wire-guided cannulation of the biliary tree during ERCP is associated with high success and low complication rates: outcomes in a single operator experience of 822 cases. J Clin Gastroenterol 2010; 44:e57-e62.
26. Lella F, Bagnolo F, Colombo E, Bonassi U. A simple way of avoiding post- ERCP pancreatitis. Gastrointest Endosc 2004; 59:830-834. (Pubitemid 38879310)
27. Cheung J, Tsoi KK, Quan WL, et al. Guidewire versus conventional contrast cannulation of the common bile duct for the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis. Gastrointest Endosc 2009; 70:1211-1219.
28. Shao LM, Chen QY, Chen MY, Cai JT. Can wire-guided cannulation reduce the risk of postendoscopic retrograde cholangiopancreatography pancreatitis? A meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2009; 24:1710-1715.
29. Nakai Y, Isayama H, Tsujino T, et al. Impact of introduction of wire-guided cannulation in therapeutic biliary ERCP. J Gastroenterol Hepatol 2011; 26:1552-1558.
30. Herreros de Tejada A, Calleja JL, D?́az G, et al., UDOGUIA-04 Group. Double-guidewire technique for difficult bile duct cannulation: a multicenter randomized, controlled trial. Gastrointest Endosc 2009; 70:700-709.
31. Xinopoulos D, Bassioukas SP, Kypreos D, et al. Pancreatic duct guidewire placement for biliary cannulation in a single-session therapeutic ERCP. World J Gastroenterol 2011; 17:1989-1995.
32. Prat F, Amaris J, Ducot B, et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 2002; 56:202-208.
33. Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion 1993; 54:105-111. (Pubitemid 23160626)
34. Schwartz JJ, Lew RJ, Ahmad NA, et al. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc 2004; 59:179-184. (Pubitemid 38199209)
35. Xu LH, Qian JB, Gu LG, et al. Prevention of postendoscopic retrograde cholangiopancreatography pancreatitis by epinephrine sprayed on the papilla. J Gastroenterol Hepatol 2011; 26:1139-1144.
36. Bai Y, Xu C, Yang X, et al. Glyceryl trinitrate for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a meta-analysis of randomized, double-blind, placebo-controlled trials. Endoscopy 2009; 41:690-695.
37. Chen B, Fan T, Wang CH. A meta-analysis for the effect of prophylactic GTN on the incidence of post-ERCP pancreatitis and on the successful rate of cannulation of bile ducts. BMC Gastroenterol 2010; 10:85.
38. Shao LM, Chen QY, Chen MY, Cai JT. Nitroglycerin in the prevention of post- ERCP pancreatitis: a meta-analysis. Dig Dis Sci 2010; 55:1-7.
39. Dumonceau JM, Andriulli A, Deviere J, et al. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis. Society of Gastrointestinal Endoscopy. Endoscopy 2010; 42:503-515.
40. Andriulli A, Leandro G, Federici T, et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007; 65:624-632. (Pubitemid 46442832)
41. Bai Y, Gao J, Zou DW, Li ZS. Prophylactic octreotide administration does not prevent postendoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. Pancreas 2008; 37:241-246.
42. Bai Y, Gao J, Shi X, et al. Prophylactic corticosteroids do not prevent post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. Pancreatology 2008; 8:504-509.
43. Zheng M, Chen Y, Bai J, et al. Meta-analysis of prophylactic allopurinol use in postendoscopic retrograde cholangiopancreatography pancreatitis. Pancreas 2008; 37:247-253.
44. Katsinelos P, Kountouras J, Paroutoglou G, et al. Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc 2005; 62:105-111. (Pubitemid 40922448)
45. Rabenstein T, Fischer B, Wiessner V, et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 2004; 59:606-613. (Pubitemid 38609687)
46. Oh HC, Cheon YK, Cho YD, Do JH. Use of udenafil is not associated with a reduction in post-ERCP pancreatitis: results of a randomized, placebocontrolled, multicenter trial. Gastrointest Endosc 2011; 74:556-562.
47. Sherman S, Cheng C-L, Costamagna G, et al. Efficacy of recombinant human interleukin-10 in prevention of postendoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas 2009; 38: 267-274.
48. George S, Kulkarni AA, Stevens G, et al. Role of osmolality of contrast media in the development of post-ERCP pancreatitis: a meta-analysis. Dig Dis Sci 2004; 49:503-508. (Pubitemid 38453572)
49. Rä ty S, Sand J, Pulkkinen M, et al. Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg 2001; 5:339-345. (Pubitemid 33651246)
50. Xiong GS, Wu SM, Zhang XW, Ge ZZ. Clinical trial of gabexate in the prophylaxis of postendoscopic retrograde cholangiopancreatography pancreatitis. Braz J Med Biol Res 2006; 39:85-90.
51. Manes G, Ardizzone S, Lombardi G, et al. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointest Endosc 2007; 65:982-987. (Pubitemid 46783824)
52. Seta T, Noguchi Y. Protease inhibitors for preventing complications associated with ERCP: an updated meta-analysis. Gastrointest Endosc 2011; 73:700.e1-2-706.e1-2.
53. Zhang ZF, Yang N, Zhao G, et al. Preventive effect of ulinastatin and gabexate mesylate on postendoscopic retrograde cholangiopancreatography pancreatitis. Chin Med J (Engl) 2010; 123:2600-2606.
54. Chen S, Shi H, Zou X, Luo H. Role of ulinastatin in preventing postendoscopic retrograde cholangiopancreatography pancreatitis: the Emperor's New Clothes or Aladdin's Magic Lamp? Pancreas 2010 39 1231-1237. statin is only effective in average risk patients when given in high doses.
55. Yoo KS, Huh KR, Kim YJ, et al. Nafamostat mesilate for prevention of postendoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial. Pancreas 2011; 40:181-186.
56. Park KT, Kang DH, Choi CW, et al. Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients? Pancreas 2011 40 1215-1219.
57. Elmunzer BJ, Waljee AK, Elta GH, et al. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008; 57:1262-1267.
58. Zheng MH, Xia HH, Chen YP. Rectal administration of NSAIDs in the prevention of post-ERCP pancreatitis: a complementary meta-analysis. Gut 2008; 57:1632-1633.
59. Dai HF, Wang XW, Zhao K. Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis: a meta-analysis. Hepatobiliary Pancreat Dis Int 2009; 8:11-16.
60. Dumonceau JM, Rigaux J, Kahaleh M, et al. Prophylaxis of post-ERCP pancreatitis: a practice survey. Gastrointest Endosc 2010; 71:934-939; 939.e1-939.e2.
61. Senol A, Saritas U, Demirkan H. Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis. World J Gastroenterol 2009; 15:3999-4004.
62. Bhatia V, Ahuja V, Acharya SK, Garg PK. A randomized controlled trial of valdecoxib and glyceryl trinitrate for the prevention of post-ERCP pancreatitis. J Clin Gastroenterol 2011; 45:170-176.
63. Jowell PS, Branch MS, Fein SH, et al. Intravenous synthetic secretin reduces the incidence of pancreatitis induced by endoscopic retrograde cholangiopancreatography. Pancreas 2011; 40:533-539.